SCHEMBL1930167

SCHEMBL1930167

COC(=O)c1nn[nH]c1C(=O)OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.53
NPSR1 Q6W5P4 2/20 0.48
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.40
STAT3 P40763 1/20 0.40
HIF1A Q16665 1/20 0.40
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 1/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.34
ALPL P05186 3/20 0.33
MAPT P10636 3/20 0.33
RAB9A P51151 2/20 0.33
POLB P06746 1/20 0.33
TP53 P04637 1/20 0.33
NPC1 O15118 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5185712 0.88 KDM4C (0.46) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL19661284 0.88 KDM4C (0.46) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL2385273 0.88 KDM4C (0.46) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL21621355 0.85 KDM4C (0.43) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL9731053 0.79 NPSR1 (0.48) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL9587880 0.79 KDM4C (0.44) KDM4CNPSR1MAPK1TSHRSMN1; SMN2
SCHEMBL23294432 0.78 KDM4C (0.43) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL3958675 0.78 KDM4C (0.43) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL9642740 0.78 KDM4C (0.43) KDM4CNPSR1MAPK1KDM4ESTAT3
SCHEMBL24844543 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395221-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS INC (US) 2021-12-23 US disclosed
US-20210395221-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS INC (US) 2021-12-23 US disclosed
US-10781200-B2 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. (US) 2020-09-22 US disclosed
US-10781200-B2 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. (US) 2020-09-22 US disclosed
EP-3229848-B1 TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP RF THERAPEUTICS INC (CA) 2020-08-12 EP disclosed
EP-3229848-B1 TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP RF THERAPEUTICS INC (CA) 2020-08-12 EP disclosed
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-10301284-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-05-28 US disclosed
US-10301284-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-05-28 US disclosed
EP-0331395-A1 Process for preparing 2-alpha-methyl-2-beta-(1,2,3-triazol-1-yl)methyl-penam-3-alpha-carboxylic acid derivatives TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1989-09-06 EP disclosed
US-4789680-A Aralkyltriazole compounds CIBA-GEIGY CORPORATION (US) 1988-12-06 US disclosed
EP-0273599-A1 Process for preparing 2beta-substituted-methyl-penicillin derivatives TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1988-07-06 EP disclosed
EP-0272016-A1 2beta-substituted-methylpenicillanic acid derivatives, and salts and esters thereof TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1988-06-22 EP disclosed
US-4673738-A Novel intermediates of cephalosporins and process for producing 7-(substituted or unsubstituted amino)-3-substituted methyl-Δ3 -cephem-4-carboxylic acids HANDI-PAC INC. (US) 1987-06-16 US disclosed
US-4616024-A Dihydropyridine anti-ischaemic and antihypertensive agents PFIZER INC. (US) 1986-10-07 US disclosed
EP-0100189-B1 DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS Pfizer Limited (GB) 1986-05-28 EP disclosed
US-4515799-A Dihydropyridine anti-ischaemic and antihypertensive agents PFIZER INC. (US) 1985-05-07 US disclosed
US-4489072-A BACTERICIDE, ANTIBIOTIC TOYAMA CHEMICAL CO., LTD. (JP) 1984-12-18 US disclosed
EP-0100189-A2 Dihydropyridine anti-ischaemic and antihypertensive agents Pfizer Limited (GB) 1984-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KDM4C 723/4885NPSR1 1946/4885MAPK1 1148/4885
US-20210395221-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KDM4C 723/4885NPSR1 1946/4885MAPK1 1148/4885
US-10781200-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 KDM4C 723/4885NPSR1 1946/4885MAPK1 1148/4885
US-10301284-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 KDM4C 723/4885NPSR1 1946/4885MAPK1 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.